Microglial autophagy-associated phagocytosis is essential for recovery from neuroinflammation.


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
16 10 2020
Historique:
received: 28 02 2020
accepted: 24 09 2020
entrez: 17 10 2020
pubmed: 18 10 2020
medline: 21 9 2021
Statut: ppublish

Résumé

Multiple sclerosis (MS) is a leading cause of incurable progressive disability in young adults caused by inflammation and neurodegeneration in the central nervous system (CNS). The capacity of microglia to clear tissue debris is essential for maintaining and restoring CNS homeostasis. This capacity diminishes with age, and age strongly associates with MS disease progression, although the underlying mechanisms are still largely elusive. Here, we demonstrate that the recovery from CNS inflammation in a murine model of MS is dependent on the ability of microglia to clear tissue debris. Microglia-specific deletion of the autophagy regulator

Identifiants

pubmed: 33067381
pii: 5/52/eabb5077
doi: 10.1126/sciimmunol.abb5077
pii:
doi:

Substances chimiques

Atg7 protein, mouse 0
Autophagy-Related Protein-1 Homolog EC 2.7.11.1
Ulk1 protein, mouse EC 2.7.11.1
Autophagy-Related Protein 7 EC 6.2.1.45

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Rasmus Berglund (R)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Andre Ortlieb Guerreiro-Cacais (AO)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Milena Z Adzemovic (MZ)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Manuel Zeitelhofer (M)

Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Solna, Sweden.

Harald Lund (H)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Ewoud Ewing (E)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Sabrina Ruhrmann (S)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Erik Nutma (E)

Department of Pathology, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.

Roham Parsa (R)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Melanie Thessen-Hedreul (M)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Sandra Amor (S)

Department of Pathology, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Robert A Harris (RA)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Tomas Olsson (T)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden.

Maja Jagodic (M)

Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden. maja.jagodic@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH